Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on ACE LIBERTY & STONE PLC. We currently have 10 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
ACE LIBERTY & STONE PLC
ACE LIBERTY & STONE PLC
Further portfolio growth and profitable disposals
27 Feb 17
The active property investment Company, capitalising on commercial property investment opportunities across the UK, has updated on two property transactions. The first is the sale of Bridge House Luton for £4.55m against the November 2014 purchase price of £2.75m, an uplift of 65% in a little over two years during which time the Company has enjoyed an annual yield of just over 10%. Ace has also announced the termination of the proposed sale of Hume House Leeds which had been agreed at £3.55m with the purchaser being unable to complete the deal. Ace retains full ownership of the building which is occupied by the Department of Work and Pensions and earns an annual rental income of £188k. The property is located in Central Leeds and Ace remains convinced the current market will provide an opportunity to sell the property in the near future which we understand is an attractive redevelopment opportunity for the right buyer.
05 Oct 16
ACE LIBERTY & STONE PLC (ALSP PZ) | DP POLAND PLC (DPP LN) | FUSIONEX INTERNATIONAL PLC (FXI LN) | GOOCH & HOUSEGO PLC (GHH LN) | KODAL MINERALS PLC (KOD LN) | OPTIBIOTIX HEALTH PLC (OPTI LN) | PARK GROUP (PKG LN) | PREMIER AFRICAN MINERALS LTD (PREM LN) | SAFECHARGE INTL GROUP LTD (SCH LN) | TIME OUT GROUP PLC (TMO LN)
Portfolio growth continues despite Brexit indigestion
05 Oct 16
The active property investment Company, capitalising on commercial property investment opportunities across the UK has released final results for the year ending 30 April 2016. The group’s property holdings grew 23% in the period to £29.5m with NAV attributable to shareholders growing by 45% to £17.9m despite the Board’s decision to reduce the valuation due to current uncertainty. Revenue increased 70% to £2m reflecting growth in a high quality tenant base. This was offset somewhat by an increase in overheads and interest payments reflecting the growing scale of the Company, which generated £421k in cash from operations in the period. The Board has taken a prudent approach to its portfolio valuation with assets held for sale being valued at £600k less than anticipated, due to certain disposals not being completed by the year end, the delay in part due to uncertainty stemming the UK’s EU referendum. Consequently, profits have been impacted with PBT of £612k vs £1.06m. The Board is seeing signs of improved activity in the market and expects that these write downs will reverse as the backlog of transactions clears. We believe the current market also provides a supportive backdrop for further opportunistic property purchases and Ace is targeting an enlargement of the portfolio to £50m without further shareholder investment.
Hybridan - Small Cap Wrap
01 Jun 16
ALSP* Board Changes, COMS Contract Win, CNS Contract Win, CCS University Partnership, DEMG announces results of ODM trial, ESP acquisition in Leicester, EZH Interim Results, EVG results, FEVR Trading Update, FDEV Update, INS acquisition, MMH Acquisition, MMX Launch, MXCP Placing, OPTI* Patent Filling, PINN Acquisition, PLI* Bought Deal, SAR* Clinical Trial, STOB Deal Completion, TERN Acquisition, TMT* Investments
Another positive verdict
20 Mar 17
Burford’s results for 2016 produced another outstanding set of figures. Revenue grew by 60% to $163.4m with strong growth in the litigation finance business and an additional boost from a secondary sale in the Petersen case. On an underlying basis net income grew to $114m, a 75% increase despite the investment in growing capacity which increased costs. A combination of ongoing investment and gains and increases on valuation saw the fair value of the litigation assets increase 67% to $559m, underpinned by a growth in invested capital to $394m. With the results statement there was an announcement of a further sale of 9% of the Petersen case at a valuation of 20 times the cost of investment.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
N+1 Singer - N1S Trend spotting - Strategy update
08 Mar 17
In this new product we present some strategy theme updates arising out of our latest analysis of macro trends and economic data and our innovative Quant work. We also look at upcoming events and suggest topping up on some of our Best Ideas for 2017.